TY - JOUR
T1 - Efficacy of trifecting® night cream, a novel triple acting skin brightening product
T2 - A double-blind, placebo-controlled clinical study
AU - Jiang, Lily
AU - Hino, Peter D.
AU - Bhatia, Ashish
AU - Stephens, Thomas J.
AU - Jimenez, Felipe
N1 - Funding Information:
FUNDING: This study was funded by Envy Medical Inc. DISCLOSURES: Dr. Bhatia is director and clinical advisor at Envy Medical Inc. and Dr. Jimenez is an employee of Envy Medical Inc. The other authors have no conflicts of interest relevant to the content of this article. CORRESPONDENCE: Felipe Jimenez, PhD; Email: fjimenez@jderm.com
Publisher Copyright:
© 2018 Matrix Medical Communications. All rights reserved.
PY - 2018/12
Y1 - 2018/12
N2 - Background: Melasma is a common, persistent disorder of hyperpigmented facial skin predominantly attributed to ultraviolet light exposure, hormonal influences, and genetic predisposition. Objectives: This double-blind, placebo-controlled, randomized clinical trial was conducted to assess the efficacy and tolerance of a multimodality night cream when used over a course of 24 weeks followed by a four-week regression in female subjects with moderate to severe melasma, presence of solar lentigines, and periocular lines and wrinkles. Methods: Subjects were randomized into one of two groups: Cell 1 received Trifecting® Night Cream (Envy Medical, Long Beach, California) 1.0 and Cell 2 did not. All subjects were supplied with a two-product regimen comprising a cleanser and sunscreen to use during the trial. Clinical grading, tolerability assessments, and Chroma Meter measurements (Konica Minolta, Tokyo, Japan) were performed at baseline and at Weeks 8, 16, 24, and 28 (regression). Standardized digital photographs were taken and self-assessment questionnaires were completed. Results: Twenty-five subjects completed the 28-week study, with 14 subjects in Cell 1 and 11 subjects in Cell 2. Subjects in both groups showed improvements in facial conditions. Cell 1 outperformed Cell 2 in improving fine lines, solar lentigines, and melasma conditions. These improvements were sustained during regression period. Conclusions: Trifecting® Night Cream 1.0, is effective for the treatment of moderate to severe melasma, solar lentigines, and periocular lines and wrinkles over 24 weeks of usage, with its benefits sustained for at least four weeks after treatment.
AB - Background: Melasma is a common, persistent disorder of hyperpigmented facial skin predominantly attributed to ultraviolet light exposure, hormonal influences, and genetic predisposition. Objectives: This double-blind, placebo-controlled, randomized clinical trial was conducted to assess the efficacy and tolerance of a multimodality night cream when used over a course of 24 weeks followed by a four-week regression in female subjects with moderate to severe melasma, presence of solar lentigines, and periocular lines and wrinkles. Methods: Subjects were randomized into one of two groups: Cell 1 received Trifecting® Night Cream (Envy Medical, Long Beach, California) 1.0 and Cell 2 did not. All subjects were supplied with a two-product regimen comprising a cleanser and sunscreen to use during the trial. Clinical grading, tolerability assessments, and Chroma Meter measurements (Konica Minolta, Tokyo, Japan) were performed at baseline and at Weeks 8, 16, 24, and 28 (regression). Standardized digital photographs were taken and self-assessment questionnaires were completed. Results: Twenty-five subjects completed the 28-week study, with 14 subjects in Cell 1 and 11 subjects in Cell 2. Subjects in both groups showed improvements in facial conditions. Cell 1 outperformed Cell 2 in improving fine lines, solar lentigines, and melasma conditions. These improvements were sustained during regression period. Conclusions: Trifecting® Night Cream 1.0, is effective for the treatment of moderate to severe melasma, solar lentigines, and periocular lines and wrinkles over 24 weeks of usage, with its benefits sustained for at least four weeks after treatment.
KW - Antioxidant
KW - Hyperpgimentation
KW - Lumixyl
KW - Melasma
KW - Photodamage
KW - Retinol
KW - Skin brightening
KW - Solar lentigines
UR - http://www.scopus.com/inward/record.url?scp=85058699306&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058699306&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85058699306
SN - 1941-2789
VL - 11
SP - 21
EP - 25
JO - Journal of Clinical and Aesthetic Dermatology
JF - Journal of Clinical and Aesthetic Dermatology
IS - 12
ER -